Ozempic Reviews: Real Results, Side Effects and What to Expect

Honest Ozempic reviews line up with what the clinical trials show: the drug lowers blood sugar, curbs appetite and leads to steady but moderate weight loss in people with type 2 diabetes, about 4 to 5 kg (9 to 10 lb) over 30 weeks at the usual doses in the trial behind its FDA label. The most common complaint is nausea, which tends to hit in the first weeks and after each dose increase. The first month at 0.25 mg is a warm-up dose that does little for blood sugar, so most people notice a clear effect after two to three months. Many stop within the first year, more often because of cost or insurance problems than because the drug failed. When it is stopped, blood sugar can rise and weight usually returns.

This page contains no anonymous or invented testimonials. It pulls together what can be checked: the FDA label, the published trials, large studies of U.S. health records, and the patterns that come up again and again in public discussions.

Ozempic results in numbers

Measure	Result	Source
A1C change, 30 weeks, 0.5 mg / 1 mg	-1.4 / -1.6 points (placebo -0.1)	FDA label, monotherapy trial
Reached A1C under 7%	73% / 70% (placebo 28%)	FDA label
Weight change, 30 weeks, 0.5 mg / 1 mg	-3.8 kg / -4.7 kg (placebo -1.2 kg)	FDA label
Weight change, 40 weeks, 2 mg	-6.9 kg (about 15 lb)	SUSTAIN FORTE
Nausea, 0.5 mg / 1 mg	15.8% / 20.3% (placebo 6.1%)	FDA label
Stopped because of stomach side effects	3.1% / 3.8% (placebo 0.4%)	FDA label
Stopped a GLP-1 drug within a year, real world, with type 2 diabetes	46.5%	JAMA Network Open, 2025

Where these reviews come from

Search for Ozempic reviews and you will find thousands of posts on forums, social media, telehealth sites and drug-rating sites. Most cannot be checked. You do not know who wrote them, whether a clinician prescribed the drug, what dose was used, whether the person has diabetes or even whether the product was genuine. So this page leans on four kinds of evidence that can be verified:

1. Randomized trials. The SUSTAIN program followed thousands of patients under the same rules and compared Ozempic with placebo or other diabetes drugs.
2. The FDA label. It reports how often side effects occurred in those trials and which serious problems have been reported since approval.
3. Real-world studies. Analyses of electronic health records from U.S. health systems show how many people keep taking the drug and why they stop.
4. Recurring themes. Where many people independently describe the same experience, we summarize it, without quoting unverifiable posts.

One distinction runs through everything below. Ozempic is approved for type 2 diabetes. Many online reviews are written by people who used it off-label for weight loss, often at different doses and with different expectations. Their stories are not wrong, but they describe a different situation. For the weight-management brand of the same drug, see Ozempic vs Wegovy and Ozempic for weight loss.

What the trials show

The FDA reviewed a program of glycemic-control trials that compared Ozempic with placebo, sitagliptin, exenatide extended-release and insulin glargine. In every comparison, A1C fell more on Ozempic. The cleanest picture comes from the 30-week monotherapy trial (SUSTAIN 1), in which 388 adults with type 2 diabetes who were not on any diabetes medicine were assigned to Ozempic 0.5 mg, 1 mg or placebo.

Trial	Dose	Length	A1C change	Weight change
SUSTAIN 1 (Ozempic alone)	0.5 mg	30 weeks	-1.4 points	-3.8 kg (8.4 lb)
SUSTAIN 1	1 mg	30 weeks	-1.6 points	-4.7 kg (10.4 lb)
SUSTAIN 1	Placebo	30 weeks	-0.1 points	-1.2 kg (2.6 lb)
SUSTAIN FORTE (with metformin)	1 mg	40 weeks	-1.9 points	-6.0 kg (13 lb)
SUSTAIN FORTE	2 mg	40 weeks	-2.2 points	-6.9 kg (15 lb)

SUSTAIN 1 figures are as reported in the FDA label; the published paper gives very similar numbers (-1.45 and -1.55 points; -3.73 and -4.53 kg). In the cardiovascular outcomes trial SUSTAIN-6, heart attack, stroke or cardiovascular death occurred in 6.6% of people on semaglutide versus 8.9% on placebo.

Keep these numbers in mind when you look at "Ozempic before and after" photos. For people with type 2 diabetes, the average weight change is a matter of several kilograms, not dozens. Dramatic transformations shared on social media are usually a different drug or a higher dose, a large lifestyle change, or the best results picked out from many. Averages also hide wide variation: some people lose much more, some almost nothing.

How long until Ozempic starts working

The most common question in the first weeks is whether the drug is doing anything. The answer lies in the dosing schedule, which starts low on purpose to give the stomach time to adjust.

Weeks 1 to 4: 0.25 mg

The FDA label is explicit that 0.25 mg is a starting dose meant to reduce stomach side effects, not a dose for controlling blood sugar. Even so, many people notice a smaller appetite, feel full sooner and may have mild nausea. Seeing little change in your glucose readings during the first month does not mean the drug has failed.

Months 2 to 3: 0.5 mg, sometimes 1 mg

After four weeks the dose goes to 0.5 mg. If more control is needed, it can go to 1 mg after at least four more weeks. This is usually when fasting and after-meal glucose readings start to improve noticeably. Stomach symptoms tend to cluster in the first months and in the days after each increase; the label notes that most reports of nausea, vomiting and diarrhea came during dose escalation.

Months 3 to 6: the first real check

A1C reflects average blood sugar over roughly three months, so that is when a clinician can judge the drug fairly. The trial results above were measured at 30 weeks, about seven months. If 1 mg is not enough after at least four weeks, the dose can go to 2 mg, the maximum.

What people praise and what they complain about

Public accounts and trial data keep returning to the same themes:

• Appetite. The most-mentioned positive change. People describe eating smaller portions, losing interest in snacks and fewer intrusive thoughts about food.
• Blood sugar. The point of the drug for most users. Readings improve over the first months, and A1C fell more on Ozempic than on comparison drugs in every trial in the label.
• Weight. Usually gradual for people with diabetes, a few pounds a month at first. Disappointment comes mostly from those who expected the larger losses seen with Wegovy.
• Nausea. The most frequent complaint. In the label's placebo-controlled trials, 15.8% on 0.5 mg and 20.3% on 1 mg reported it, against 6.1% on placebo. It was mostly mild to moderate and temporary.
• Vomiting, diarrhea, constipation. Vomiting affected 5% to 9.2%, diarrhea about 8.5% to 8.8%, constipation 3.1% to 5%. Indigestion, belching, bloating and reflux were also more common than with placebo.
• Fatigue and dizziness. Listed in the label among other reactions associated with Ozempic. People who eat very little because of low appetite seem to mention them more.
• Cost and coverage. A constant theme in U.S. reviews: prior authorization, plan denials, and prices that changed several times in 2025 and 2026. See Ozempic cost.
• Shortages. From 2022 until the FDA declared the semaglutide shortage over on February 21, 2025, many people could not fill prescriptions and had to pause treatment.

Overall, stomach side effects occurred in 32.7% of people on 0.5 mg and 36.4% on 1 mg in the placebo-controlled pool, versus 15.3% on placebo. Rare but serious problems such as pancreatitis, gallbladder disease and severe stomach slowing are covered in Ozempic side effects.

What clinicians see in practice

Doctors who prescribe GLP-1 drugs tend to make the same points. Ozempic is not a cure; it works while you take it. Habits around eating, activity and sleep decide much of what happens after treatment ends. Nausea is the main reason some people give up, and it is often manageable with slower dose increases, smaller meals and patience. And patients do better when they eat enough protein and keep up strength training, because rapid weight loss takes some muscle with it.

A cautionary pattern also shows up: people who got "Ozempic" from somewhere other than a pharmacy. Online sellers use the name for compounded products, research-only peptides and outright fakes. The FDA has warned that counterfeit Ozempic has been found in the United States, and products labeled "for research purposes" or "not for human consumption" are not approved medicines. A bad experience with one of those is not a review of Ozempic.

Recurring themes on forums

We do not quote forum posts, because the author, dose and diagnosis cannot be checked. But the topics that keep coming up are worth knowing, since you will probably face some of them:

• getting through nausea in the first weeks and after a dose increase;
• having so little appetite that eating enough, especially protein, is hard;
• constipation and bloating;
• insurance denials, prior authorization and switching between plans;
• whether alcohol is allowed and how to eat (see Ozempic and alcohol);
• weight loss that stalls after a few months;
• appetite and weight returning after stopping.

One kind of advice should never be followed from a forum: changing your dose on your own, "counting clicks" to get extra doses from a pen, or buying the drug without a prescription. Those are decisions for your prescriber. The reasons are explained in Ozempic dosage.

How long people stay on Ozempic

Ozempic is not a course you finish. For type 2 diabetes it is meant as long-term treatment for as long as it helps and you tolerate it, with your clinician reviewing A1C, weight, kidney function and how you feel. In reality, many people stop sooner than planned.

A study of electronic health records from a collective of U.S. health systems, published in JAMA Network Open in 2025, followed 125,474 adults with overweight or obesity who started semaglutide, liraglutide or tirzepatide between 2018 and 2023. Within one year, 46.5% of those with type 2 diabetes and 64.8% of those without it had stopped. Among people who stopped, 47.3% of those with diabetes and 36.3% of those without it restarted within a year. Greater weight loss was linked to a lower chance of stopping; moderate or severe stomach side effects to a higher one.

Why people stop was examined by Cleveland Clinic researchers in a random sample of 288 adults without diabetes who started injectable semaglutide or tirzepatide for obesity and stopped within a year:

Main reason for stopping	Share
Cost or insurance problems	47.6%
Could not tolerate side effects	14.6%
Could not fill because of shortages	11.8%
Switched to a compounded product	2.4%
Not enough weight loss	1.7%
Other reasons	10.8%
Not recorded	11.1%

These figures cover people treated for obesity, not diabetes, and include tirzepatide, so they do not translate directly to every Ozempic user. They still make the point: the drug failing to work was rarely the reason. Money and tolerability were.

The same research group found that real-world results run below trial results. In a 2024 study of 3,389 patients with obesity in Ohio and Florida, average weight change at one year was -5.1% on semaglutide; it was -3.2% when the drug was prescribed for type 2 diabetes versus -5.9% for obesity. People who stayed on treatment without long gaps, and those on higher doses, did better.

What happens when you stop Ozempic

Ozempic's half-life is about one week, so it leaves the body over several weeks and appetite returns gradually rather than overnight. For someone with diabetes, the bigger issue is blood sugar: without the drug it can rise again, which is why stopping should be planned with your prescriber, who will usually substitute another treatment.

Weight is the other issue. The clearest data come from semaglutide 2.4 mg (Wegovy) in people without diabetes. In the STEP 1 trial extension, people regained about two-thirds of the weight they had lost within a year of stopping, and improvements in blood pressure and other markers largely reversed. The Cleveland Clinic data point the same way: people who stopped early lost much less weight at one year (3.6%) than those who continued (11.9%).

If cost is the reason you are thinking of stopping, ask first about lower-priced options: a manufacturer savings offer, NovoCare's self-pay price, the Ozempic tablets, a covered alternative on your plan's formulary or Novo Nordisk's Patient Assistance Program. Switching to tirzepatide is another route; see switching from Ozempic to Mounjaro.

How to read Ozempic reviews critically

1. Check that it is the same drug. "Ozempic soft," Ozempic capsules, drops, gummies and patches are not Novo Nordisk products. The only real forms are the weekly pen and the daily Ozempic tablet. See Ozempic pill and Ozempic patch.
2. Watch for sellers posing as users. A review with a link to buy, a discount code or an invitation to message privately is advertising.
3. Look for context. Does the person have diabetes? What dose, for how long, with what other changes? Without that, a result says little.
4. Treat before-and-after photos as marketing. Lighting, angle, posture and editing apps change a picture, and only the best cases are posted.
5. One story is not a pattern. Very good and very bad experiences can both be exceptions. Compare them with trial data covering thousands of people.
6. A review is not a prescription. Whether to start, change or stop depends on your conditions and other medicines, so the decision belongs with your clinician.

Questions to ask your prescriber

• What A1C and weight goals are realistic for me, and when will we check?
• How fast should I go up in dose, and can we slow it if I have nausea?
• Do any of my other medicines, such as insulin or a sulfonylurea, need adjusting?
• What should I eat, and how much protein do I need?
• What is the plan if my insurance stops covering it?
• What happens if I want to stop?

The bottom line

Reliable Ozempic reviews describe a moderate but clear effect on blood sugar and weight, frequent and usually temporary nausea, and benefits that last only while the drug is taken. Most people who stop do so because of cost or side effects rather than lack of effect. For an overview of the drug, start with the Ozempic guide; for how it compares with tirzepatide, see Ozempic vs Mounjaro. This page is general information, not medical advice.